1.57% -0.0139

Scynexis Inc (SCYX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt SCYX? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Scynexis Inc Stock (SCYX) Company Profile

Scynexis Inc

Healthcare (1118)

201-884-5485

1 EVERTRUST PLAZA, JERSEY CITY, NJ

Nächster Verdiensttermin

Neueste SEC-Einreichungen

SCYX's Discussions on Twitter

Compare SCYX vs TAK, ZTS, HLN, TEVA, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SCYX Scynexis Inc	0.8764	37.36M	20.60M	-8.61M	-5.28M	-0.1381
TAK Takeda Pharmaceutical Co Adr	17.84	56.14B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	114.75	48.74B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.04	44.85B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	28.73	34.12B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	540.89	23.35B	3.13B	1.27B	1.12B	26.39

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-01-22	Eingeleitet	Guggenheim	Buy
2021-01-06	Eingeleitet	Cantor Fitzgerald	Overweight
2018-07-11	Hochstufung	Needham	Hold → Buy
2018-06-27	Eingeleitet	Maxim Group	Buy
2017-10-24	Eingeleitet	Guggenheim	Buy
2017-07-10	Eingeleitet	ROTH Capital	Buy
2017-05-09	Herabstufung	Needham	Buy → Hold
2017-03-03	Bestätigt	RBC Capital Mkts	Outperform
2016-10-20	Eingeleitet	H.C. Wainwright	Buy
2016-10-07	Hochstufung	WBB Securities	Buy → Strong Buy
2016-10-03	Fortgesetzt	Brean Capital	Buy
2016-08-17	Eingeleitet	Guggenheim	Buy
2016-08-09	Bestätigt	Needham	Buy
2016-08-09	Hochstufung	WBB Securities	Speculative Buy → Buy
2016-03-28	Eingeleitet	Brean Capital	Buy
2015-12-29	Eingeleitet	WBB Securities	Speculative Buy
2015-11-16	Bestätigt	RBC Capital Mkts	Outperform
2015-06-10	Eingeleitet	Needham	Buy
2014-05-29	Eingeleitet	Canaccord Genuity	Buy
2014-05-29	Eingeleitet	RBC Capital Mkts	Outperform

Alle ansehen

Scynexis Inc Aktie (SCYX) Neueste Nachrichten

Finanzdaten der Scynexis Inc-Aktie (SCYX)

Scynexis Inc (SCYX)

Scynexis Inc Stock (SCYX) Company Profile

Compare SCYX vs TAK, ZTS, HLN, TEVA, UTHR

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Scynexis Inc Aktie (SCYX) Neueste Nachrichten

SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy - Insider Monkey

Brookline Capital cuts SCYNEXIS stock price target on valuation By Investing.com - Investing.com South Africa

Brookline Capital cuts SCYNEXIS stock price target on valuation - Investing.com Nigeria

Is SCYNEXIS Inc stock overvalued or fairly priced2025 EndofYear Setup & Growth Focused Investment Plans - baoquankhu1.vn

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Scynexis Inc earnings beat by $0.12, revenue topped estimates - Investing.com Nigeria

Scynexis Q4 2025 Earnings: Profit of $12.3M, Full-Year 2025 Revenue $20.6MNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform

Scynexis: Fourth Quarter Financial Results Overview - Bitget

Scynexis: Q4 Earnings Snapshot - marketscreener.com

SCYNEXIS Q4 Earnings Assessment - Benzinga

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update - Bitget

SCYNEXIS Reports Q4 2025 Milestones and Financial Results, Including $24.8 Million Payment from GSK and Advancements in SCY-247 Development - Quiver Quantitative

Fast-track antifungal SCY-247, $24.8M GSK deal extend SCYNEXIS cash runway - Stock Titan

Scynexis (SCYX) advances SCY-247 antifungal and reshapes GSK ibrexafungerp deal - Stock Titan

SCYX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

SCYNEXIS (SCYX) Projected to Post Quarterly Earnings on Wednesday - Defense World

SCYNEXIS (NASDAQ:SCYX) Stock Price Passes Above 50 Day Moving Average – What’s Next? - Defense World

SCYNEXIS, Inc. (SCYX) Competitors - Meyka

Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC - GuruFocus

SCYNEXIS (SCYX) Initiates Phase 1 Trial for New Antifungal Thera - GuruFocus

SCYNEXIS doses first patients in SCY-247 IV formulation trial By Investing.com - Investing.com Canada

SCYNEXIS doses first patients in SCY-247 IV formulation trial - Investing.com

SCYNEXIS, Inc. Initiates Phase 1 Trial for Intravenous Antifungal SCY-247 Following FDA Designations - Quiver Quantitative

SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247 - The Manila Times

SCYNEXIS starts dosing trial for antifungal targeting resistant infections - Stock Titan

Can SCYNEXIS Inc. disrupt its industryJuly 2025 Trade Ideas & AI Driven Price Predictions - mfd.ru

Does SCYNEXIS Inc. align with a passive investing strategyTrade Entry Report & Expert-Curated Trade Recommendations - mfd.ru

Short Squeeze: Will SCYNEXIS Inc benefit from rate cutsJuly 2025 PostEarnings & Real-Time Chart Pattern Alerts - baoquankhu1.vn

Kingdon Capital exits Scynexis (SCYX) stake in amended 13G/A filing - Stock Titan

Can SCYNEXIS Inc. expand into new marketsWeekly Risk Report & Consistent Growth Equity Picks - mfd.ru

Market Moves: Is SCYNEXIS Inc backed by strong institutional buyingQuarterly Portfolio Report & AI Forecast Swing Trade Picks - baoquankhu1.vn

Invasive Fungal Infections Market to Witness Upsurge in Growth at a CAGR of 11.4% (in the US) During the Forecast Period (2025-2034) | DelveInsight - The Malaysian Reserve

FOMO Trade: Does SCYNEXIS Inc have pricing powerJuly 2025 Levels & Community Driven Trade Alerts - baoquankhu1.vn

Swing Trade: Is SCYNEXIS Inc backed by strong institutional buyingMarket Performance Summary & Weekly Consistent Profit Watchlists - baoquankhu1.vn

SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting - marketscreener.com

Scynexis (SCYX) to Present Data on Advanced Antifungal Drug at K - GuruFocus

SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) - The Manila Times

New antifungal SCY-247 shows potent activity against deadly drug-resistant fungi - stocktitan.net

Companies Like SCYNEXIS (NASDAQ:SCYX) Could Be Quite Risky - Sahm

Aug Macro: Can SCYNEXIS Inc expand into new marketsQuarterly Earnings Summary & Safe Entry Trade Reports - baoquankhu1.vn

JERSEY CITYFDA grants fast track and QIDP designations to SCYNEXIS drug - Investing.com Nigeria

Scynexis (SCYX) Gains FDA Designations for Antifungal Therapy SC - GuruFocus

Scynexis receives FDA qualified infectious disease product and fast track designations for SCY-247 - marketscreener.com

SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 - The Manila Times

FDA fast-tracks new antifungal aimed at deadly Candida auris infections - Stock Titan

Breakout Move: Is SCYNEXIS Inc benefiting from innovation trendsMarket Sentiment Review & Risk Controlled Stock Pick Alerts - baoquankhu1.vn

Aug Volume: Is SCYNEXIS Inc stock trending bullishWeekly Trade Analysis & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn

FEDERATED HERMES, INC. Acquires Additional Shares in SCYNEXIS Inc. - GuruFocus

Retail Trends: Can SCYNEXIS Inc expand into new marketsWeekly Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn

RSI Check: Is SCYNEXIS Inc benefiting from innovation trendsWeekly Trend Report & AI Based Buy/Sell Signal Reports - baoquankhu1.vn

Jobs Data: Will SCYNEXIS Inc stock continue dividend increasesJuly 2025 Levels & Community Driven Trade Alerts - Bộ Nội Vụ

Finanzdaten der Scynexis Inc-Aktie (SCYX)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie SCYX